



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: January 30, 2009

To: Primary Clinical Research Associates

From: Sara Braun
Research Protocol Specialist III

Re: N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

The “Folstein Mini Mental State Form” has been updated to reflect Appendix IV rather than Appendix V. Also, the title of the “NCCTG Research Blood Specimen Form” has been revised to reflect “NCCTG Research Blood **Requisition** Form.”

Please incorporate these revised forms into your forms packet. If you have any questions, please feel free to contact me.

Enclosure